However, as DGKα is upregulated and oncogenic in various human cancers (Chen et al., 2019; Fazio et al., 2020; Mérida et al., 2017; Sakane et al., 2021), the findings from our study suggest that Ras-driven polarity-impaired cancers may be particularly dependent on DGKα for tumour survival and, therefore, that DGKα inhibitors and Ras pathway inhibitors would be a highly effective drug combination for anti-cancer therapy in these cancers. The gene discussed is DGKA; the disease is cancer.